PURPOSE: To investigate international patterns of practice in the management of radiation therapy-induced nausea and vomiting (RINV). METHODS AND MATERIALS: Oncologists prescribing radiation therapy in the United States, Canada, The Netherlands, Australia, New Zealand, Spain, Italy, France, Hong Kong, Singapore, Cyprus, and Israel completed a Web-based survey that was based on 6 radiation therapy-only clinical cases modeled after the minimal-, low-, moderate-, and high-emetic risk levels defined in the antiemetic guidelines of the American Society of Clinical Oncology and the Multinational Association of Supportive Care in Cancer. For each case, respondents estimated the risks of nausea and vomiting separately and committed to an initial management approach. RESULTS: In total, 1022 responses were received. Risk estimates and management decisions for the minimal- and high-risk cases varied little and were in line with guideline standards, whereas those for the low- and moderate-risk cases varied greatly. The most common initial management strategies were as follows: rescue therapy for a minimal-risk case (63% of respondents), 2 low-risk cases (56% and 80%), and 1 moderate-risk case (66%); and prophylactic therapy for a second moderate-risk case (75%) and a high-risk case (95%). The serotonin (5-HT)₃ receptor antagonists were the most commonly recommended prophylactic agents. On multivariate analysis, factors predictive of a decision for prophylactic or rescue therapy were risk estimates of nausea and vomiting, awareness of the American Society of Clinical Oncology antiemetic guideline, and European Society for Therapeutic Radiology and Oncology membership. CONCLUSIONS: Risk estimates and management strategies for RINV varied, especially for low- and moderate-risk radiation therapy cases. Radiation therapy-induced nausea and vomiting are under-studied treatment sequelae. New observational and translational studies are needed to allow for individual patient risk assessment and to refine antiemetic guideline management recommendations.
PURPOSE: To investigate international patterns of practice in the management of radiation therapy-induced nausea and vomiting (RINV). METHODS AND MATERIALS: Oncologists prescribing radiation therapy in the United States, Canada, The Netherlands, Australia, New Zealand, Spain, Italy, France, Hong Kong, Singapore, Cyprus, and Israel completed a Web-based survey that was based on 6 radiation therapy-only clinical cases modeled after the minimal-, low-, moderate-, and high-emetic risk levels defined in the antiemetic guidelines of the American Society of Clinical Oncology and the Multinational Association of Supportive Care in Cancer. For each case, respondents estimated the risks of nausea and vomiting separately and committed to an initial management approach. RESULTS: In total, 1022 responses were received. Risk estimates and management decisions for the minimal- and high-risk cases varied little and were in line with guideline standards, whereas those for the low- and moderate-risk cases varied greatly. The most common initial management strategies were as follows: rescue therapy for a minimal-risk case (63% of respondents), 2 low-risk cases (56% and 80%), and 1 moderate-risk case (66%); and prophylactic therapy for a second moderate-risk case (75%) and a high-risk case (95%). The serotonin (5-HT)₃ receptor antagonists were the most commonly recommended prophylactic agents. On multivariate analysis, factors predictive of a decision for prophylactic or rescue therapy were risk estimates of nausea and vomiting, awareness of the American Society of Clinical Oncology antiemetic guideline, and European Society for Therapeutic Radiology and Oncology membership. CONCLUSIONS: Risk estimates and management strategies for RINV varied, especially for low- and moderate-risk radiation therapy cases. Radiation therapy-induced nausea and vomiting are under-studied treatment sequelae. New observational and translational studies are needed to allow for individual patient risk assessment and to refine antiemetic guideline management recommendations.
Authors: Mary Lou Affronti; Sarah Woodring; Karen Allen; John Kirkpatrick; Katherine B Peters; James E Herndon; Frances McSherry; Patrick N Healy; Annick Desjardins; James J Vredenburgh; Henry S Friedman Journal: Support Care Cancer Date: 2016-06-06 Impact factor: 3.603
Authors: Kristopher Dennis; Liying Zhang; Stephen Lutz; Yvette van der Linden; Angela van Baardwijk; Tanya Holt; Jean-Leon Lagrange; Palmira Foro-Arnalot; Lea-Choung Wong; Ernesto Maranzano; Kam-Hung Wong; Rico Liu; Vassilios Vassiliou; Benjamin W Corn; Carlo De Angelis; Lori Holden; C Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2013-02-26 Impact factor: 3.603
Authors: Christina H Ruhlmann; Franziska Jahn; Karin Jordan; Kristopher Dennis; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Petra Feyer Journal: Support Care Cancer Date: 2016-09-13 Impact factor: 3.603
Authors: Kristopher Dennis; Rehana Jamani; Clare McGrath; Leila Makhani; Henry Lam; Patrick Bauer; Carlo De Angelis; Natalie Coburn; C Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2017-03-31 Impact factor: 3.603
Authors: Michael Poon; Jonathan Hwang; Kristopher Dennis; Carlo DeAngelis; Liying Zhang; Hans Chung; Jordan Stinson; Shun Wong; Natalie Pulenzas; Edward Chow Journal: Support Care Cancer Date: 2015-09-16 Impact factor: 3.603
Authors: E Wong; N Pulenzas; G Bedard; C DeAngelis; L Zhang; M Tsao; C Danjoux; N Thavarajah; B Lechner; R McDonald; P M Cheon; E Chow Journal: Curr Oncol Date: 2015-06 Impact factor: 3.677
Authors: Paulien G Westhoff; Alexander de Graeff; Evelyn M Monninkhof; Ilse de Pree; Marco van Vulpen; Jan Willem H Leer; Corrie A M Marijnen; Yvette M van der Linden Journal: J Radiat Oncol Date: 2017-09-19